Dr Andy Yale

BVMedSci (Hons) BVM BVS (Hons) PGCertVetEd PGDipVCP MVetMed DipECVIM-CA (Oncology) FHEA MRCVS
Lecturer in Veterinary Oncology (CET)

Department: Clinical Science and Services

Campus: Hawkshead

Research Groups: CPCS (Research Programme)

Clinical Groups: Small Animal Oncology

Andy is an RCVS and European Veterinary Specialist in Small Animal Oncology and Lecturer in Veterinary Oncology at the RVC, working in the Queen Mother Hospital for Animals. Andy supervises and trains oncology residents, teaches undergraduate students, sees small animal oncology patients, and undertakes research.

Andy graduated from The University of Nottingham and initially spent two years in small animal general practice. He subsequently undertook a small animal rotating internship and medical oncology residency at the Royal Veterinary College, also completing a postgraduate diploma and master's degree. He gained his Diploma in Small Animal Oncology from the European College of Veterinary Internal Medicine (ECVIM) and is now a Lecturer in Veterinary Oncology. 

Clinically, Andy has a particular interest in canine mast cell tumours and leveraging sentinel lymph mapping to improve the accuracy of cancer staging. His research interests focus on the diagnostic, therapeutic and prognostic role of the oncobiome, particularly the intestinal microbiome. He is also interested in novel diagnostic and therapeutic strategies in veterinary cancer patients, particularly those where there is translational relevance.

Andy leads the RVC's Comparative Physiology and Clinical Science (CPCS) Oncology Research Group, and is also a member of the RVC's clinical research ethical review board (CRERB). He holds a Home Office personal license (PIL) under the Animals (Scientific Procedures) Act. He is Associate Editor of Veterinary Oncology. Andy is a trustee of the Zeus and PJ Charitable Foundation, a charity aimed at funding lifesaving cancer treatment for dogs whose owners are not able to do so. 

Andy contributes to the wider veterinary profession by providing oncology CPD, and is a regular invited speaker at numerous national and international conferences.

ResearchGate profile: HERE

Peer reviewed research publications:

Machado D, Picornell JA, Amores-Fuster I, Benjamin S, Kearns T, Zajc AL, Bing Y, McNaught KA, Sava M, Johnston C, Rolf B, Yale AD. Mediastinal lymphoma in 70 dogs treated with lomustine or anthracycline-based multi-agent chemotherapy. Vet Comp Oncol. 2026. https://doi.org/10.1111/vco.70062

Figueroa C, Yale AD, Syme H, Yaffy D, Harsum G, Giullén A. Clinico-pathological features and outcome of cats with thyroid carcinoma. Vet. Oncol. 2, 20 (2025). https://doi.org/10.1186/s44356-025-00033-4

Ancheta K, Psifidi A, Yale AD, Le Calvez S, Williams J. Deep-learning based morphological segmentation of canine diffuse large B-cell lymphoma. Frontiers in Veterinary Science. 2025;12 https://doi.org/10.3389/fvets.2025.1656976

Guillén A, Kropp K, Rogato F, Yale AD, Hetesy G, Beguin J, Erles K, Priestnall SL, Reyes-Gomez E, Hardas A. Evaluation of tumour biomarkers associated with invasion, metastasis and immune escape in cats with exocrine pancreatic carcinoma. J Comp Path. 2025 https://doi.org/10.1016/j.jcpa.2025.05.009.

Yale AD, So A, Guillén A, Desmas-Bazelle I, Rogato F, Jepson RE. Evaluation of Decreased Kidney Function in Dogs Receiving Carboplatin: A Retrospective Cohort Study of 98 Dogs (2006–2024). Vet Comp Oncol. 2025 https://doi.org/10.1111/vco.13069

Rogato F,  Szladovits B,  Martineau H, Yale AD, Mitchell J, Holmes E, Gardner R, Guillén A. Leukemia cutis as a prominent clinical sign in a dog with acute myeloid leukemia. Vet Clin Pathol.  2024; 00: 1-10. https://doi.org/10.1111/vcp.13382 

Yale AD, Crawford A, Gramer I, Guillen A, Desmas I, Holmes E. Large granular lymphocyte lymphoma in 65 dogs (2005 - 2023). Vet Comp Oncol. 2023. https://doi.org/10.1111/vco.12959

Marks T, Rossanese M, Yale AD, Stewart S, Smallwood K, Guillen A. Prognostic factors and outcome in cats with thymic epithelial tumours: 64 cases (1999 - 2021). J Small Anim Pract. 2023. https://doi.org/10.1111/jsap.13675

McNally A, Rossanese M, Suárez-Bonnet A, Hardas A, Yale AD. Urinary bladder hemangiosarcoma in a cat treated with partial cystectomy and adjuvant metronomic cyclophosphamide and thalidomide. J Vet Intern Med. 2023; 1- 5. https://doi.org/10.1111/jvim.16750

Treggiari E, Pellin M, Romanelli G, Maresca G, Gramer I, Yale AD, Pecceu E, Pegnanelli M, Borrego J, Purzycka K, Berlato D. Tonsillar carcinoma in dogs: Treatment outcome and potential prognostic factors in 123 cases. J Vet Intern Med. 2023;1- 11. https://doi.org/10.1111/jvim.16623

Yale AD, Priestnall S, Pittaway R, Taylor A. Thymic epithelial tumours in 51 dogs: Histopathologic and clinicopathologic findings. Vet Comp Oncol. 2021;20(1):50-58. https://doi.org/10.1111/vco.12705

Yale AD, Szladovits B, Stell A, Fitzgerald S, Priestnall S, Suarez-Bonnet A. High-Grade Cutaneous Mast Cell Tumour with Widespread Intrathoracic Metastasis and Neoplastic Pericardial Effusion in a Dog. J Comp Pathol. 2020;180:29-34. https://doi.org/10.1016/j.jcpa.2020.08.006

Andy is involved with the supervision and training of oncology residents, in addition to teaching undergraduate BVetMed students throughout their 3rd, 4th and 5th years of study. He is rotation leader for the 5th year veterinary students' oncology rotation. Andy has completed a postgraduate certificate in veterinary education and is a Fellow of the Higher Education Academy.

Associate Editor of Veterinary Oncology.

Peer reviewer for Veterinary and Comparative Oncology, Veterinary Oncology, Topics in Companion Animal Medicine, and Vet Record Case Reports.

Member of assessment panel for RCVS Advanced Practitioner Status. 

Trustee of Zeus & PJ Charitable Foundation, a charity aimed at funding cancer treatment in dogs where owners are unable to do so.

Top of page